Table 2

All-cause mortality at year 5, divided by baseline FGF23, PTH and 25(OH)vit D status

VariableNumber (% of
total cohort, n=1664)
Died prior to end of year 5 follow-up (%)Univariable HRs (95% CI)HRs for all-cause mortality at end of year 5 follow-up period (95% CI)
Model 1Model 2Model 3
FGF23 (pg/mL)
 <25100 (6.0)15 (15.0)1 (ref)1 (ref)1 (ref)1 (ref)
 25–511089 (65.4)172 (15.8)1.08 (0.63 to 1.82)0.81 (0.48 to 1.38)0.90 (0.52 to 1.57)0.93 (0.54 to 1.62)
 52–70319 (19.2)63 (19.7)1.40 (0.80 to 2.47)0.77 (0.44 to 1.37)0.89 (0.49 to 1.61)0.88 (0.49 to 1.60)
 >70156 (9.4)39 (25.0)1.86 (1.03 to 3.38)*0.90 (0.49 to 1.66)0.88 (0.47 to 1.67)0.88 (0.47 to 1.67)
PTH (pg/mL)
 <35436 (26.2)54 (12.4)1 (ref)1 (ref)1 (ref)1 (ref)
 35–65806 (48.4)115 (14.3)1.19 (0.86 to 1.64)0.89 (0.64 to 1.24)0.84 (0.61 to 1.17)0.84 (0.61 to 1.18)
 66–95286 (17.2)75 (26.2)2.39 (1.69 to 3.40)*1.41 (0.99 to 2.02)1.30 (0.90 to 1.87)1.30 (0.89 to 1.89)
 >95136 (8.2)45 (33.1)3.15 (2.12 to 4.68)*1.59 (1.06 to 1.09)*1.38 (0.91 to 2.08)1.37 (0.89 to 2.12)
25(OH)Vit D (nmol/L)
 <25104 (6.3)34 (32.7)2.76 (1.79 to 4.26)*2.17 (1.40 to 3.35)*1.96 (1.26 to 3.05)*1.62 (1.01 tro 2.58)*
 25–50648 (38.9)117 (18.1)1.35 (0.97 to 1.87)1.16 (0.84 to 1.61)1.03 (0.74 to 1.45)0.94 (0.67 to 1.33)
 51–75553 (33.2)86 (15.6)1.09 (0.78 to 1.54)1.07 (0.76 to 1.51)1.04 (0.73 to 1.47)1.01 (0.71 to 1.43)
 >75359 (21.6)52 (14.5)1 (ref)1 (ref)1 (ref)1 (Ref)
  • Model 1 – adjusted HRs for age, baseline eGFR, gender and uACR

  • Model 2 – HRs adjusted for variables in model 1, diabetes, previous cardiovascular disease, haemoglobin, bicarbonate and albumin

  • Model 3 – HRs adjusted for variables included in model 2 plus vitamin D insufficiency (<50 nmol/L), elevated PTH (>65 pg/mL) and elevated FGF23 (>51 pg/mL) as appropriate

  • *p<0.05

  • eGFR, estimated glomerular filtration rate; FGF, fibroblast growth factor; PTH, parathyroid hormone; uACR, urinary albumin to creatinine ratio; 25(OH)Vit D, 25-hydroxy-Vitamin D.